-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from 2020 to Q1 2025.
- Aerovate Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2025 was -$2.38M, a 89.9% increase year-over-year.
- Aerovate Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the twelve months ending March 31, 2025 was -$49.9M.
- Aerovate Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was -$71.2M, a 25.4% decline from 2023.
- Aerovate Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$56.8M, a 45.1% decline from 2022.
- Aerovate Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$39.1M, a 42.8% decline from 2021.
Net Cash Provided by (Used in) Operating Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)